Cite
Pal SK, McGregor B, Suárez C, et al. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol. 2021;39(33):3725-3736doi: 10.1200/JCO.21.00939.
Pal, S. K., McGregor, B., Suárez, C., Tsao, C. K., Kelly, W., Vaishampayan, U., Pagliaro, L., Maughan, B. L., Loriot, Y., Castellano, D., Srinivas, S., McKay, R. R., Dreicer, R., Hutson, T., Dubey, S., Werneke, S., Panneerselvam, A., Curran, D., Scheffold, C., Choueiri, T. K., & Agarwal, N. (2021). Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(33), 3725-3736. https://doi.org/10.1200/JCO.21.00939
Pal, Sumanta K, et al. "Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,33 (2021): 3725-3736. doi: https://doi.org/10.1200/JCO.21.00939
Pal SK, McGregor B, Suárez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol. 2021 Nov 20;39(33):3725-3736. doi: 10.1200/JCO.21.00939. Epub 2021 Sep 07. PMID: 34491815; PMCID: PMC8601305.
Copy
Download .nbib